Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

CBL404

Sigma-Aldrich

Anti-p53 Antibody, aa 211-220, clone240

clone PAb240, Chemicon®, from mouse

Synonim(y):

Przeciwciało anty-p53

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

pochodzenie biologiczne

mouse

Poziom jakości

forma przeciwciała

purified antibody

rodzaj przeciwciała

primary antibodies

klon

PAb240, monoclonal

reaktywność gatunkowa

hamster, monkey, mouse, chicken, human, rat, bovine

producent / nazwa handlowa

Chemicon®

metody

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

izotyp

IgG1

przydatność

not suitable for immunohistochemistry (Paraffin)

numer dostępu NCBI

numer dostępu UniProt

Warunki transportu

wet ice

informacje o genach

human ... TP53(7157)

Opis ogólny

p53 was discovered in 1979 as a cellular protein associating with the transforming protein of SV40 tumor virus. Since then, many different biochemical functions have been attributed to the 53 kD phosphoprotein. Experimental evidence has suggested that p53 acts as a negative regulator of cell growth in normal cells (Finlay, 1989). Thus, the inactivation or mutation of p53 may be an essential step in the development of malignancy (Lane and Benchmol, 1990). Wild-type p53 levels in normal cells and tissues were found to be very low. Mutant p53 polypeptide, however, is often found to be present at high concentrations in mammalian tumors and tumor cell lines. For example, in an immuno-histochemistry study 40% of human breast cancer showed elevated levels of mutant p53 in the cell nucleus. Mutations of the p53 protein have some characteristic features:

a) Most of them are missense point mutations giving rise to an altered protein function.

b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.

Specyficzność

PAb 240 recognizes an epitope of p53 tumor suppressor protein between amino acids 211 and 220 (Gannon, 1990; Legros, 1994) in human, mouse, rat, hamster, monkey, cow and chicken. Assaying native samples (immunoprecipitation, ELISA) the PAb 240 detects only the mutant forms of p53 (Gannon, 1990; Said, 1994). In methods using denatured samples [Western blot analysis (Gannon, 1990) and immunohistochemistry of frozen tissue sections (Said, 1994; Bartek, 1991; Walker, 1991)], the PAb 240 recognizes both mutant and denatured wild-type p53.

Immunogen

Epitope: aa 211-220
Murine p53-beta galactosidase fusion protein expressed in E. coli.

Zastosowanie

Detect p53 with Anti-p53 Antibody, aa 211-220, clone240 (Mouse Monoclonal Antibody), that has been shown to work in IP, WB & IHC.
Detection of p53 oncogene protein

Detection of mutant p53

Prevalence of detection using CBL 404

-50% colon carcinoma sections positive (30 samples)

-70% lung carcinoma sections positive (50 samples)

-30% carcinoma breast samples positive (50 samples)

Normal and pre-malignant tissues negative

Reacts on methacarn fixed tissue

Optimal working dilutions must be determined by the end user.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors

Powiązanie

Replaces: 04-1083

Postać fizyczna

Format: Purified
Purified mouse monoclonal in buffer containing 0.1M Tris-glycine (pH 7.4), 0.15M NaCl, with 0.05% sodium azide. We recommend that each laboratory determine an optimum working titre for use in its particular application.

Przechowywanie i stabilność

For use within 1 month of purchase store at +4°C, for long term storage aliquot antibody into small volumes and store at -20°C.

Informacje prawne

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Nie możesz znaleźć właściwego produktu?  

Wypróbuj nasz Narzędzie selektora produktów.

Kod klasy składowania

12 - Non Combustible Liquids

Klasa zagrożenia wodnego (WGK)

WGK 1

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Iggo, R, et al.
Lancet, 335, 675-679 (1990)
Rajan Gogna et al.
The Journal of biological chemistry, 287(4), 2907-2914 (2011-12-08)
Mutant (Mt) p53 abrogates tumor suppression functions of wild-type (WT) p53 through mutant-specific, gain-of-function effects, and patients bearing Mt p53 are chemoresistant. The dominant negative effect of p53 mutants results from their aggregation propensity which causes co-aggregation of WT p53.
Siddharth Singh et al.
The Journal of biological chemistry, 294(38), 14081-14095 (2019-08-02)
TP53 is the most frequently mutated tumor suppressor gene in many cancers, yet biochemical characterization of several of its reported mutations with probable biological significance have not been accomplished enough. Specifically, missense mutations in TP53 can contribute to tumorigenesis through
The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain
Srinivasan, A, et al
Molecular and cellular biology, 17, 4761-4773 (1997)
Eric Chekwube Aniogo et al.
Molecules (Basel, Switzerland), 26(23) (2021-12-11)
Multidrug resistance (MDR) has posed a significant threat to cancer treatment and has led to the emergence of a new therapeutic regime of photodynamic therapy (PDT) to curb the menace. The PDT modality employs a photosensitiser (PS), excited at a

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej